Asset Details
Do you wish to reserve the book?
OTHER RADIOPHARMACEUTICALS FOR IMAGING GEP-NET
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
OTHER RADIOPHARMACEUTICALS FOR IMAGING GEP-NET
Do you wish to request the book?
OTHER RADIOPHARMACEUTICALS FOR IMAGING GEP-NET
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Book Chapter
OTHER RADIOPHARMACEUTICALS FOR IMAGING GEP-NET
2015
Overview
In GEP‐NETs, especially the catecholamine and serotonin biosynthetic pathways are upregulated. Therefore, increased biosynthesis of these specific amines in GEP‐NETs enables imaging with specific amine precursors. For the catecholamine pathway, 6‐
18
F ‐
l
‐3,4‐dihydroxyphenylalanine (
18
F‐DOPA) is available, while for the serotonin pathway, carbon‐11‐labeled 5‐hydroxy‐
l
‐tryptophan ([
11
C]‐5‐HTP) is available as tracer.
11
C‐5‐HTP PET and
18
F‐DOPA PET are excellent functional imaging techniques for evaluating patients with proven pancreatic islet cell tumors and carcinoids. For both tracers, the combination with CT further improves the detection rate of NET, which shows that performing PET scans with these tracers in PET/CT scanners is beneficial for patients.
Since well‐differentiated GEP‐NETs generally have a low glucose metabolism,
18
F‐fluorodexyglucose (
18
F‐FDG) PET scanning has limited value for the primary staging of patients with well‐differentiated GEP‐NETs. However, in patients with rapidly progressive disease, dedifferentiation of GEP‐NET tumors can lead to a higher glucose metabolism in tumor cells. In these patients,
18
F‐FDG PET can be of benefit for tumor staging. Also,
18
F‐FDG PET can be of value when other malignancies are suspected in patients with GEP‐NETs, since these patients experience a higher incidence of these malignancies compared to the general population.
Nowadays, (GEP)‐NETs can also be imaged with
68
Ga‐labeled analogues of somatostatin, which are also PET tracers. Advantages of
68
Ga‐labeled somatostatin analogues are the relatively easy generator‐based synthesis and the possibility to evaluate whether peptide (somatostatin) receptor radionuclide therapy (PRRT) for NETs can be considered.
Publisher
John Wiley & Sons, Incorporated,John Wiley & Sons, Inc
Subject
ISBN
1118521536, 9781118521533
